Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 40

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Influenza

Not yet recruiting

Safety and immune response of OVX836C2 vaccine compared with drug combination in healthy adults with influenza

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Osivax

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Non-small cell lung cancer stage III

Not yet recruiting

Fluorescence bronchoscopy to assess durvalumab-680LT distribution in unresectable stage III non‑small cell lung cancer patients after chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitair Medisch Centrum Groningen

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Sepsis+3

Not yet recruiting

Comparison of ampicillin plus gentamicin versus piperacillin/tazobactam for empirical treatment of hospitalized patients with community‑acquired infection

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Region Hovedstaden

Pulmonary hypertension

Not yet recruiting

Discontinuing vs Continuing Riociguat in Chronic Thromboembolic Pulmonary Hypertension Patients After Successful Balloon Pulmonary Angioplasty

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Assistance Publique Hopitaux De Paris

Tonsillitis

Not yet recruiting

Intravenous benzathine benzylpenicillin added to oral phenoxymethylpenicillin for relief in adults with acute tonsillitis, peritonsillar phlegmon and abscess

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Region Midtjylland

Malignant pleural effusion

Not yet recruiting

Study of Hyperthermic Intrathoracic Chemotherapy with Cisplatin and Pleurectomy versus Standard Care in Patients with Malignant Pleural Effusion

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Universita' Degli Studi Di Torino

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Interstitial lung disease

Not yet recruiting

Immunomodulatory Treatment with Prednisone, Azithromycin and Hydroxychloroquine in Patients with Surfactant‑Related Gene Mutation Interstitial Lung Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Assistance Publique Hopitaux De Paris

Asthma

Not yet recruiting

Study of Three Doses of Frevecitinib (KN-002) in Adults with Severe Asthma Not Controlled by Medium‑to‑High Dose Inhaled Steroid/LABA Therapy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate

Chronic obstructive pulmonary disease

Not yet recruiting

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.